Focus:
by Reynald Castaneda in London. Myovant Sciences’ Phase III relugolix trial in castrate-sensitive prostate cancer reporting of a positive trend in reducing major cardiovascular (CV) issues drew mostly expert scepticism. The...
by Manasi Vaidya in New York. AstraZeneca’s Tagrisso (osimertinib) may not find widespread adoption in the adjuvant setting for non-small cell lung cancer (NSCLC), despite positive Phase III data, in the...
The Multidisciplinary Association for Psychedelic Studies (MAPS) is developing the first-in-class innovator drug midomafetamine (MDMA) for use in treating chronic and delayed-onset post-traumatic stress disorder (PTSD). The drug is currently...
Since early March, hundreds of organisations that are acting as the sponsor, collaborator, or contract research organisation (CRO) have publicly announced disruptions to planned and ongoing clinical trials in their...
Treatment of melanoma has switched gears after immune checkpoint inhibitor (ICI) therapies were first introduced in 2011. Currently, the combination of anti-programmed cell death protein 1 (PD-1) inhibitor nivolumab (Opdivo)...
New advancements in the treatment of ovarian cancer have transformed the lives of many women. The introduction of targeted therapies such as anti-angiogenic agent bevacizumab (Avastin) and three poly-ADP ribose...
The FDA has extended its review of Novartis multiple sclerosis (MS) drug, ofatumumab, until September 2020. The review was originally expected to occur in June 2020. Ofatumumab is a fully-humanised...
As the Covid-19 pandemic continues around the world, companies and researchers are continuously working to find a vaccine or a therapeutic. Drug candidates are currently going through the stages of...
HER-2 targeting in gastric cancer has not occurred to the same magnitude as in breast cancer, with one of the reasons being a lower patient population that overexpresses HER-2 in...
by Jennifer C Smith in London. The advent of Covid-19 has left pharma companies in the psychiatry space, in particular, scrambling to understand the pandemic’s impact on patient-reported outcomes (PROs)...
